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Post‐traumatic osteoarthritis (PTOA) is a painful and debilitating disease that is caused by mechanical destabilization of the joint and injury to the articular cartilage; however, the molecular and cellular mechanisms leading to cartilage degeneration due to trauma are not well understood. It has been demonstrated that inflammation,[1](#jor23263-bib-0001){ref-type="ref"} abnormal subchondral bone properties[2](#jor23263-bib-0002){ref-type="ref"} and loss of response to mechanical load[3](#jor23263-bib-0003){ref-type="ref"} all contribute to the development of OA. Many individuals developing OA are asymptomatic until significant joint damage has occurred,[4](#jor23263-bib-0004){ref-type="ref"} at which point the only available long‐term treatment options are surgical replacement of the joint and/or pain management.[5](#jor23263-bib-0005){ref-type="ref"} Therefore, identifying and characterizing OA biomarkers for detecting and tracking the progression of the disease combined with developing new pharmacologic interventions aimed to minimize cartilage damage triggered by joint injury, are vital scientific endeavors.

In the past decade, using human biopsy and animal OA models, new insights about joint OA pathogenesis were uncovered. To date, several studies have evaluated molecular changes associated with human arthritic joint tissues including: Synovium,[6](#jor23263-bib-0006){ref-type="ref"} meniscus,[7](#jor23263-bib-0007){ref-type="ref"} cartilage,[8](#jor23263-bib-0008){ref-type="ref"}, [9](#jor23263-bib-0009){ref-type="ref"} osteophytes,[10](#jor23263-bib-0010){ref-type="ref"} and subchondral bone.[11](#jor23263-bib-0011){ref-type="ref"} Many of these studies revealed molecular changes associated with late stages of OA but only a few examined earlier molecular events because of clinical limitations. It is difficult to discriminate asymptomatic OA tissues and compare it to age matched healthy controls. Instead, mouse models that mimic human OA have been used with great success to study OA pathogenesis and to identify putative molecular and genetic factors driving the progression of the disease.[12](#jor23263-bib-0012){ref-type="ref"}, [13](#jor23263-bib-0013){ref-type="ref"}

Though OA is commonly diagnosed by visible damage to the articular cartilage, more recent assessments of OA have been migrating to evaluate the entire joint, and perceive the disease as a multi factorial, multi cell‐type phenotype.[14](#jor23263-bib-0014){ref-type="ref"}, [15](#jor23263-bib-0015){ref-type="ref"} In this study, we used a non‐invasive tibial compression (TC) mouse model that closely mimics traumatic anterior cruciate ligament (ACL) rupture in humans to study molecular mechanisms driving PTOA development and progression.[16](#jor23263-bib-0016){ref-type="ref"} We hypothesized that a global gene expression profiling of TC injured knee joints at early (1 day or 1 week post injury) and late (6 or 12 weeks post injury) time points will unveil novel candidate genes and molecular mechanisms responsible for PTOA development and progression, and reveal new insights into OA progression in TC model. Through RNA sequencing analysis (RNAseq) we identified 1446 differentially regulated genes in injured joints, including several long noncoding RNAs (lncRNAs) that have not been previously studied in the context of PTOA. Furthermore, we compared our data with gene expression data generated from the surgical destabilization of the medial meniscus (DMM)[17](#jor23263-bib-0017){ref-type="ref"}, [18](#jor23263-bib-0018){ref-type="ref"} model of PTOA, to understand the commonalities and differences between these two models.

MATERIALS AND METHODS {#jor23263-sec-0003}
=====================

Animals and Tibial Compression (TC) Joint Injury {#jor23263-sec-0004}
------------------------------------------------

Wildtype C57B/L6 mice underwent injury by applying a TC load (10--12 N) to the right knee of 16 weeks old male mice, as previously described.[16](#jor23263-bib-0016){ref-type="ref"} All animal experiments were conducted in accordance with institutional animal care and use committee guidelines at Lawrence Livermore National Laboratory and University of California, Davis.

Histology {#jor23263-sec-0005}
---------

Injured and uninjured (contralateral) joints were collected at 1 day, 1‐, 6‐, and 12 weeks (*n* = 5 per group) post injury. Joints were dissected, fixed in 4% paraformaldehyde, decalcified using 0.5 M EDTA, infiltrated in increasing concentrations of isopropanol, equilibrated into mineral oil, and embedded into paraffin wax. Six micrometer paraffin sections were stained on glass slides using 0.1% Safranin‐O and 0.05% Fast Green using standard procedures (IHC world) and imaged using a Leica DM5000 microscope. Three blind reviewers independently assessed OA severity using a modified OARSI[19](#jor23263-bib-0019){ref-type="ref"} scale to examine the medial compartment of injured and uninjured joints (sagittal views) (grade scale 0--0.5 normal; 1--2 mild; 3--4 moderate; 5--6 severe cartilage damage).

Micro‐Computed Tomography (micro‐CT) Analysis and Osteophyte Quantification {#jor23263-sec-0006}
---------------------------------------------------------------------------

Quantification of epiphyseal trabecular bone of the distal femur and osteophyte volume was carried out as previously described.[20](#jor23263-bib-0020){ref-type="ref"} In brief, fixed joints were embedded into 1.5% agarose to a desired angle and scanned with micro‐computed tomography (SCANCO micro‐CT 35, Brüttisellen, Switzerland). Analysis was performed to quantify the microstructure of trabecular bone of the distal femoral epiphysis and osteophyte formation surrounding the joint. Joints were imaged under the guidelines for micro‐CT analysis for rodent bone structure (X‐ray tube potential = 55 kVp, intensity = 114 mA, 10 mm isotropic nominal voxel size, integration time = 900 ms).[21](#jor23263-bib-0021){ref-type="ref"} Quantification of trabecular bone volume fraction (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and other microstructural parameters was done using the tools provided by the manufacturer.[16](#jor23263-bib-0016){ref-type="ref"} Lastly, osteophyte volume was calculated at terminal time points (6 and 12 weeks post injury), and included all mineralized tissues in the joint space except naturally ossified structures (patella, fabella, and anterior/posterior horns of the menisci). Statistical analysis was performed using a paired *t*‐test to compare injured and contralateral knees.

RNA Isolation and Sequencing (RNAseq) {#jor23263-sec-0007}
-------------------------------------

Injured and contralateral joints (1 day \[*n* = 5\], 1‐ \[*n* = 5\], 6‐ \[*n* = 3\], and 12‐weeks \[*n* = 3\]) were dissected and cut at the base edges of femoral and tibial joint regions with small traces of soft tissues to preserve the intact knee joint. Dissected joints (between 0.25 and 0.3 g total weight) were then cut into small pieces and submerged in RNA Later (Qiagen) and stored at 4°C until processing. RNA Later solution was removed and dissected joints were homogenized in Qiazol lysis solution (Qiagen); RNA was isolated utilizing RNeasy Qiagen kits according to manufacturer\'s instructions. Isolated RNA (between 1 and 2 µg) was sequenced using an Illumina HiSeq 2000.

RNAseq Data Analysis {#jor23263-sec-0008}
--------------------

RNAseq data quality was checked using "FastQC" (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc>). Sequence reads were aligned to mouse genome (mm10) using "TopHat."[22](#jor23263-bib-0022){ref-type="ref"} Differential gene expression analysis was conducted using an FPKM (fragments per kilobase of transcript per million mapped reads) based strategy and a count based strategy, to reduce the number of false positive discoveries. In the FPKM based strategy differentially expressed genes (DEGs) were identified using "Cufflinks" and "Cuffdiff."[23](#jor23263-bib-0023){ref-type="ref"} A gene was considered significantly differentially expressed when its false discovery rate (FDR) corrected *p*‐value was \< 0.05 and fold change was greater than 1.5. Subsequently, DEGs were filtered based on their expression values and low expressing genes with FPKM value \< 2 were removed. In the count based strategy "featureCounts"[24](#jor23263-bib-0024){ref-type="ref"} was used to perform read summarization on reads mapped with "TopHat." Subsequently, the data was normalized using "voom"[25](#jor23263-bib-0025){ref-type="ref"} and DEGs with fold change \> 1.5 and *p*‐value \< 0.05 were identified using "limma."[26](#jor23263-bib-0026){ref-type="ref"} Genes identified by both methods as significantly differentially expressed were used to generate a list of high‐confidence DEGs. These high‐confidence DEGs were used for further analyses. Venn diagrams were created using R package "VennDiagram." Heatmap was generated using heatmap.2 function in R package "gplots."

Microarray Data Analysis {#jor23263-sec-0009}
------------------------

Previously published microarray data were downloaded from Gene Expression Omnibus (GEO) and the data analysis was conducted using Bioconductor.[27](#jor23263-bib-0027){ref-type="ref"} Affymetrix data[7](#jor23263-bib-0007){ref-type="ref"}, [10](#jor23263-bib-0010){ref-type="ref"}, [28](#jor23263-bib-0028){ref-type="ref"} preprocessing and normalization were performed using RMA method.[29](#jor23263-bib-0029){ref-type="ref"} Agilent data[17](#jor23263-bib-0017){ref-type="ref"} were background corrected with Normexp, normalized within arrays with loess and between arrays with Aquantile.[26](#jor23263-bib-0026){ref-type="ref"} Differentially expressed genes were identified using "limma."[26](#jor23263-bib-0026){ref-type="ref"} Genes with *p*‐value \< 0.05, FDR corrected *p*‐value \< 0.1 and fold change \> 1.5 were considered significantly differentially expressed.

Functional Annotation {#jor23263-sec-0010}
---------------------

Gene ontology analysis was performed using DAVID[30](#jor23263-bib-0030){ref-type="ref"} and enriched gene ontology terms (*p*‐value \< 0.01) were identified. Long noncoding RNA (*lncRNA*) gene annotations were obtained from GENCODE.[31](#jor23263-bib-0031){ref-type="ref"} ToppCluster was used to cluster differentially expressed genes from different time points based on phenotype enrichment[32](#jor23263-bib-0032){ref-type="ref"} and Cytoscape was used for cluster visualization.[33](#jor23263-bib-0033){ref-type="ref"} Mouse phenotype data was obtained from MGI database (<http://www.informatics.jax.org/>).

RESULTS {#jor23263-sec-0011}
=======

Molecular Changes Associated With PTOA Development {#jor23263-sec-0012}
--------------------------------------------------

Knee injury was induced by applying a single compressive load (10--12 N) to the right knee (Fig. [1](#jor23263-fig-0001){ref-type="fig"}A), as previously described.[16](#jor23263-bib-0016){ref-type="ref"}, [34](#jor23263-bib-0034){ref-type="ref"} Injured and contralateral joints were examined histologically and by RNAseq at 1 day, 1‐, 6‐, and 12 weeks post injury (Fig. [1](#jor23263-fig-0001){ref-type="fig"}B). Contralateral controls revealed minimal pathological changes at all times examined (Fig. [1](#jor23263-fig-0001){ref-type="fig"}C). Furthermore, no obvious morphological changes were observed histologically at 1 day post injury (Fig. [1](#jor23263-fig-0001){ref-type="fig"}D), suggesting that no articular fracture or damage was initially introduced by the compressive load and knee dislocation. As previously reported, we observed severe cartilage erosion (Fig. [1](#jor23263-fig-0001){ref-type="fig"}E and F) with osteophyte formation (Fig. [1](#jor23263-fig-0001){ref-type="fig"}G--I) at 6‐ and 12 weeks post injury.[16](#jor23263-bib-0016){ref-type="ref"}, [34](#jor23263-bib-0034){ref-type="ref"} Significant subchondral bone loss was also observed at 6‐ and 12 weeks post injury (Fig. [1](#jor23263-fig-0001){ref-type="fig"}J).

![Histological evaluations of tibial compression (TC) OA injury. (A) TC overload leads to joint destabilization though ACL dislocation. The direction of joint displacement is indicated by the red arrow. (B) Time line where mice were injured and joints were collected at 1 day, 1‐, 6‐, and 12 weeks for either histology or RNA sequencing. Histological assessment of uninjured (C) and injured joints at various time points post injury (D--F) by Safranin‐O and Fast Green staining. Micro‐CT highlight regions (dark gray) of osteophyte formation in 6‐ (G) and 12‐ (H) weeks injured joints. (I) Micro‐CT quantification of osteophyte formation in injured joints. (J) Quantification of femoral subchondral trabecular bone formation between injured and uninjured joints. All histological images were presents were taken at 10× magnification. Scale bar is 1 mm; \*\* *p *\< 0.01.](JOR-35-474-g001){#jor23263-fig-0001}

The FPKM and the count based methods (Fig. [2](#jor23263-fig-0002){ref-type="fig"}A) jointly identified a total of 1446 DEGs (Suppl. Table S1), where 599, 644, 511, and 201 DEGs were found at 1 day, 1‐, 6‐, and 12 weeks post injury, respectively (Fig. [2](#jor23263-fig-0002){ref-type="fig"}B and C). At 1 day, several genes up/down‐regulated in injured joints in response to injury were also found to be up/down‐regulated in contralateral joints compared to age matched WT controls. However, by 1 week post injury the expression of many of the genes reverted back to WT control levels (Suppl. Fig. S1). The largest overlap among the DEGs was found between 1 day and 1 week post injury, where 272 up‐ and 23 down‐regulated genes were in common (Fig. [2](#jor23263-fig-0002){ref-type="fig"}B and C). We also identified 15 genes that were up‐regulated at all time points examined (Table [1](#jor23263-tbl-0001){ref-type="table-wrap"}). Interestingly, no genes were found to be down‐regulated at all time points. Genes up‐regulated at all time points included extracellular matrix (ECM) components (*Fn1*,[9](#jor23263-bib-0009){ref-type="ref"} collagens 3, 5, and 6,[35](#jor23263-bib-0035){ref-type="ref"}, [36](#jor23263-bib-0036){ref-type="ref"} *Cthrc1*, *Thbs3*), matrix metabolic enzymes (*Mmp3* [37](#jor23263-bib-0037){ref-type="ref"}) and Wnt signaling proteins (*Sfrp2* and *Wisp2*). In addition, it included ECM and cell adhesion proteins (SRPX2 and TNN) and a synovial fibroblast cell surface marker[38](#jor23263-bib-0038){ref-type="ref"} (THY1). We also identified 18 *lncRNAs* including *Dnm3os*, *Rian*, *H19*, and *Snhg18* differentially regulated in injured knee joints compared to uninjured controls (Table [2](#jor23263-tbl-0002){ref-type="table-wrap"}).

![RNA sequencing analysis methodology and differentially expressed transcripts. (A) Flowchart of RNAseq data analysis. All of the differentially regulated genes presented were identified by both the FPKM based method and the count based method as significantly differentially expressed (*p* \< 0.05). Common differentially up (B) and down (C) regulated genes between every time point post TC injury. The total number of genes per category is in brackets beneath each time point.](JOR-35-474-g002){#jor23263-fig-0002}

###### 

Transcripts That Were Up‐Regulated in Injured Joints, at All Time Points Examined

  No.   Gene Name   1 Day   1 Week   6 Weeks   12 Weeks
  ----- ----------- ------- -------- --------- ----------
  1     *Mmp3*      4.46    5.68     11.74     6.14
  2     *Col3a1*    4.10    5.74     4.05      3.93
  3     *Cthrc1*    3.83    5.05     1.86      2.92
  4     *Sfrp2*     3.41    4.61     3.18      3.03
  5     *Wisp2*     3.08    2.67     1.81      2.67
  6     *Tnn*       2.69    4.22     3.17      3.02
  7     *Col5a1*    2.52    3.80     2.43      2.17
  8     *Col6a3*    2.24    4.39     3.14      2.39
  9     *Srpx2*     2.21    2.94     2.53      2.48
  10    *Thy1*      2.11    2.50     2.18      2.52
  11    *Col6a2*    2.10    4.31     2.41      2.81
  12    *Col6a1*    2.07    4.17     2.29      2.44
  13    *Col5a2*    2.05    2.89     2.70      2.65
  14    *Thbs3*     1.80    3.95     4.10      2.50
  15    *Fn1*       1.58    3.02     4.46      2.93

Values represent the fold changes between injured and uninjured joints (*p* \< 0.05).

© 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

###### 

Long Noncoding RNAs Differentially Expressed in Injured Joints

  No.   *LncRNA Name*                                        1 Day    1 Week   6 Weeks   12 Weeks
  ----- ---------------------------------------------------- -------- -------- --------- ----------
  1     *Dnm3os* [^a^](#jor23263-note-0002){ref-type="fn"}   0.672    1.324    ns        ns
  2     *Rian*                                               0.942    2.002    ns        ns
  3     *2810433D01Rik*                                      1.022    ns       ns        ns
  4     *H19* [^b^](#jor23263-note-0003){ref-type="fn"}      ns       0.98     ns        ns
  5     *Snhg18*                                             ns       0.777    ns        1.028
  6     *2610203C20Rik*                                      ns       0.892    ns        ns
  7     *Gm11974*                                            ns       ns       1.706     ns
  8     *E330020D12Rik*                                      ns       ns       1.807     ns
  9     *AI504432*                                           ns       ns       0.942     ns
  10    *Tmem134*                                            ns       ns       ns        0.981
  11    *2310065F04Rik*                                      −1.044   ns       ns        ns
  12    *C130080G10Rik*                                      −2.921   ns       ns        ns
  13    *1810044D09Rik*                                      ns       −1.007   ns        ns
  14    *Plet1os*                                            ns       −0.988   ns        ns
  15    *2610306M01Rik*                                      ns       ns       −0.616    ns
  16    *0610040B10Rik*                                      ns       ns       −1.647    ns
  17    *BC018473*                                           ns       ns       −1.04     ns
  18    *2610035D17Rik*                                      ns       ns       −0.87     ns

*lncRNAs* previously shown to function during skeletal development;

or be dysregulated in OA cartilage.

Values represent the log2 fold changes between injured and uninjured joints (*p* \< 0.05)

© 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Gene Ontology Analysis of Differentially Regulated Genes {#jor23263-sec-0013}
--------------------------------------------------------

For up‐regulated genes, gene ontology categories corresponding to *vasculature development*, *cell adhesion, extracellular matrix organization, extracellular structure organization*, and *collagen fibril organization* were enriched at all time points examined (Table [3](#jor23263-tbl-0003){ref-type="table-wrap"}). Categories corresponding to *regulation of cell proliferation* and *chondroitin sulfate proteoglycan metabolic process* were enriched at all but the 12 week time point. *Angiogenesis* and *hypoxia* genes were enriched only at 1 day and 1 week post injury, while categories covering *bone* and *cartilage development* and collagen catabolism were enriched only at 1‐ and 6 weeks post injury correlating with the emergence of osteophyte formation and cartilage degradation as observed by histological analysis and micro‐CT (Fig. [1](#jor23263-fig-0001){ref-type="fig"}E and F). *Wnt signaling* was enriched only at 1 week, while genes associated with *cell cycle* were enriched at 6 weeks post injury. Categories corresponding to *immune responses* were enriched at 1 day, 6‐ and 12 weeks post injury, while markers of *inflammation* were enriched at 1 day and 12 weeks post injury. Inflammation related genes up‐regulated at 12 weeks post injury include several complement pathway components such as *C1qa*, *C1qc*, *Cfb*, and *Cfp*. These data suggest that significant cartilage remodeling occurs shortly after injury, while immune responses oscillate, with an early phase at 1 day and a later phase initiating at 6 weeks post injury.

###### 

Geneo Ontology Enriched Categories for Differentially Expressed Genes, at All Time Points Examined

                                                                                                        1 Day   1 Week     6 Weeks   12 Weeks                        
  ---------------------- ------------------------------------------------------------------------------ ------- ---------- --------- ---------- ---- ---------- ---- ----------
  Up‐regulated genes                                                                                                                                                 
  GO:0001944             Vasculature development                                                        29      5.08E‐11   25        2.59E‐08   14   6.20E‐04   8    0.00671
  GO:0007155             Cell adhesion                                                                  41      4.26E‐09   63        3.16E‐23   41   6.48E‐14   17   3.33E‐05
  GO:0030198             Extracellular matrix organization                                              17      5.39E‐09   25        4.35E‐17   17   3.13E‐11   8    3.04E‐05
  GO:0030199             Collagen fibril organization                                                   7       1.06E‐05   7         1.04E‐05   9    1.66E‐09   5    3.08E‐05
  GO:0043062             Extracellular structure organization                                           18      2.64E‐07   29        7.22E‐17   19   1.87E‐10   8    3.50E‐04
  GO:0042127             Regulation of cell proliferation                                               25      0.00604    26        0.00291    23   2.98E‐04   ns   ns
  GO:0050654             Chondroitin sulfate proteoglycan metabolic process                             4       0.00728    5         5.96E‐04   5    1.58E‐04   ns   ns
  GO:0009611             Response to wounding                                                           27      9.91E‐07   18        0.00789    ns   ns         12   2.49E‐04
  GO:0001525             Angiogenesis                                                                   14      3.66E‐05   12        6.04E‐04   ns   ns         ns   ns
  GO:0001666             Response to hypoxia                                                            7       0.00581    8         0.00119    ns   ns         ns   ns
  GO:0006954             Inflammatory response                                                          23      7.64E‐08   ns        ns         ns   ns         10   1.70E‐04
  GO:0006955             Immune response                                                                33      4.93E‐07   ns        ns         18   0.00523    16   1.68E‐05
  GO:0060348             Bone development                                                               ns      ns         15        1.83E‐06   14   2.01E‐07   ns   ns
  GO:0051216             Cartilage development                                                          ns      ns         10        1.61E‐04   11   1.30E‐06   ns   ns
  GO:0001501             Skeletal system development                                                    ns      ns         30        2.19E‐10   22   4.84E‐08   ns   ns
  GO:0001503             Ossification                                                                   ns      ns         14        2.94E‐06   14   5.57E‐08   ns   ns
  GO:0030574             Collagen catabolic process                                                     ns      ns         4         0.00860    5    2.04E‐04   ns   ns
  GO:0001558             Regulation of cell growth                                                      ns      ns         13        3.69E‐06   ns   ns         5    0.00890
  GO:0006508             Proteolysis                                                                    ns      ns         ns        ns         ns   ns         19   0.00414
  GO:0006956             Complement activation                                                          ns      ns         ns        ns         ns   ns         4    0.00388
  GO:0016477             Cell migration                                                                 ns      ns         18        1.47E‐04   ns   ns         8    0.00540
  GO:0002062             Chondrocyte differentiation                                                    ns      ns         ns        ns         6    2.94E‐05   ns   ns
  GO:0002063             Chondrocyte development                                                        ns      ns         ns        ns         3    0.00844    ns   ns
  GO:0002694             Regulation of leukocyte activation                                             ns      ns         ns        ns         11   4.79E‐04   ns   ns
  GO:0006029             Proteoglycan metabolic process                                                 ns      ns         6         0.00139    8    1.63E‐06   ns   ns
  GO:0006260             DNA replication                                                                ns      ns         ns        ns         10   0.00174    ns   ns
  GO:0006790             Sulfur metabolic process                                                       ns      ns         ns        ns         7    0.00703    ns   ns
  GO:0007017             Microtubule‐based process                                                      ns      ns         ns        ns         12   0.00157    ns   ns
  GO:0007049             Cell cycle                                                                     ns      ns         ns        ns         29   5.47E‐06   ns   ns
  GO:0008630             DNA damage response, signal transduction resulting in induction of apoptosis   ns      ns         ns        ns         4    0.00785    ns   ns
  GO:0009100             Glycoprotein metabolic process                                                 ns      ns         ns        ns         11   3.31E‐04   ns   ns
  GO:0030203             Glycosaminoglycan metabolic process                                            ns      ns         ns        ns         6    7.19E‐04   ns   ns
  GO:0031214             Biomineral formation                                                           ns      ns         ns        ns         7    3.38E‐05   ns   ns
  GO:0006928             Cell motion                                                                    ns      ns         22        4.97E‐04   ns   ns         ns   ns
  GO:0016055             Wnt receptor signaling pathway                                                 ns      ns         12        4.98E‐04   ns   ns         ns   ns
  GO:0048870             Cell motility                                                                  ns      ns         18        0.00103    ns   ns         ns   ns
  GO:0051674             Localization of cell                                                           ns      ns         18        0.00103    ns   ns         ns   ns
  GO:0000904             Cell morphogenesis involved in differentiation                                 ns      ns         15        0.00111    ns   ns         ns   ns
  GO:0007169             Transmembrane receptor protein tyrosine kinase signaling pathway               ns      ns         13        0.00386    ns   ns         ns   ns
  GO:0007167             Enzyme linked receptor protein signaling pathway                               ns      ns         16        0.00453    ns   ns         ns   ns
  GO:0001649             Osteoblast differentiation                                                     ns      ns         6         0.00672    ns   ns         ns   ns
  GO:0048771             Tissue remodeling                                                              ns      ns         6         0.00672    ns   ns         ns   ns
  GO:0006897             Endocytosis                                                                    ns      ns         12        0.00911    ns   ns         ns   ns
  GO:0030036             Actin cytoskeleton organization                                                ns      ns         11        0.00987    ns   ns         ns   ns
  GO:0006935             Chemotaxis                                                                     11      4.81E‐04   ns        ns         ns   ns         ns   ns
  GO:0010876             Lipid localization                                                             10      0.00565    ns        ns         ns   ns         ns   ns
  GO:0022604             Regulation of cell morphogenesis                                               9       0.00341    ns        ns         ns   ns         ns   ns
  GO:0030029             Actin filament‐based process                                                   13      0.00193    ns        ns         ns   ns         ns   ns
  GO:0045597             Positive regulation of cell differentiation                                    13      0.00184    ns        ns         ns   ns         ns   ns
  Down‐regulated genes                                                                                                                                               
  GO:0005996             Monosaccharide metabolic process                                               8       5.51E‐05   9         2.11E‐05   6    0.00834         
  GO:0046164             Alcohol catabolic process                                                      4       0.00455    4         0.00731    4    0.00886         
  GO:0006096             Glycolysis                                                                     ns      ns         4         2.43E‐03   4    2.96E‐03        
  GO:0006091             Generation of precursor metabolites and energy                                 ns      ns         10        2.95E‐05   16   1.28E‐10        
  GO:0014706             Striated muscle tissue development                                             ns      ns         6         0.00107    5    0.00965         
  GO:0045668             Negative regulation of osteoblast differentiation                              3       0.00167    ns        ns         ns   ns              
  GO:0006071             Glycerol metabolic process                                                     3       6.17E‐03   ns        ns         ns   ns              
  GO:0006094             Gluconeogenesis                                                                4       1.40E‐04   ns        ns         ns   ns              
  GO:0006641             Triglyceride metabolic process                                                 4       8.28E‐04   ns        ns         ns   ns              
  GO:0030278             Regulation of ossification                                                     4       0.00255    ns        ns         ns   ns              
  GO:0016051             Carbohydrate biosynthetic process                                              4       8.97E‐03   ns        ns         ns   ns              
  GO:0016052             Carbohydrate catabolic process                                                 5       7.97E‐04   ns        ns         ns   ns              
  GO:0008610             Lipid biosynthetic process                                                     8       6.43E‐04   ns        ns         ns   ns              
  GO:0007517             Muscle organ development                                                       ns      ns         9         1.17E‐05   ns   ns              
  GO:0003012             Muscle system process                                                          ns      ns         6         5.40E‐05   ns   ns              
  GO:0009408             Response to heat                                                               ns      ns         4         9.59E‐04   ns   ns              
  GO:0046034             ATP metabolic process                                                          ns      ns         ns        ns         8    1.96E‐06        
  GO:0006119             Oxidative phosphorylation                                                      ns      ns         ns        ns         6    3.16E‐05        
  GO:0022900             Electron transport chain                                                       ns      ns         ns        ns         7    9.14E‐05        
  GO:0015992             Proton transport                                                               ns      ns         ns        ns         5    3.66E‐04        

© 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

For down‐regulated genes *monosaccharide metabolic process* and *alcohol catabolic process* were enriched at all but the 12 weeks post injury time point. Categories corresponding to *glycolysis*, *generation of precursor metabolites and energy*, and *striated muscle tissue development* were enriched at 1 week and 6 weeks post injury. Genes associated with *negative regulation of osteoblast differentiation*, and *carbohydrate* and *lipid biosynthetic processes* were enriched at 1 day, while *muscle organ development*, *muscle system process*, and *response to heat* were enriched at 1 week post injury. Categories corresponding to *ATP metabolic process*, *oxidative phosphorylation*, and *electron transport chain* were enriched at 6 weeks post injury. We found several components of mitochondrial electron transport chain including *Ndufa1*, *Ndufa2*, *Ndufb3*, and *Uqcr10* to be down‐regulated at 6 weeks post injury suggesting aberrant mitochondrial activity. The 12 week time point did not reveal enrichment for any ontology categories.

Phenotype Enrichment Analysis {#jor23263-sec-0014}
-----------------------------

We performed a comparative phenotype enrichment analysis using ToppCluster[32](#jor23263-bib-0032){ref-type="ref"} and identified enriched mouse phenotypes associated with the DEGs. For up‐regulated genes, *inflammatory/immune response* related phenotypes and *muscle* phenotypes were found to be enriched at 1 day post injury, whereas both 1‐ and 6 weeks data showed enrichment for *cartilage* and *bone* phenotypes. Three categories: *Arthritis, abnormal cutaneous collagen fibril morphology*, and *abnormal tendon morphology* were enriched at all time points, except 12 weeks post injury. We identified 26 genes with *arthritis* phenotypes up‐regulated at 1 day, 1‐ and/or 6 weeks (Fig. [3](#jor23263-fig-0003){ref-type="fig"}).

![Enriched phenotypes associated with genes up‐regulated at 1 day (D1), 1‐ (W1), 6‐ (W6), and 12 weeks (W12) post injury. Up‐regulated genes associated with Arthritis phenotypes are highlighted at the bottom, left side.](JOR-35-474-g003){#jor23263-fig-0003}

While 1 day, 1‐ and 6 weeks data shared a significant overlap, the 12 weeks post injury data did not have any overlap with any other time points, and showed enrichment for only two categories: *Abnormal response to infection* and *increased susceptibility to infection*, suggesting that the severe cartilage damage observed histologically at this point (Fig. [1](#jor23263-fig-0001){ref-type="fig"}F) may render the organism susceptible to secondary health consequences due to viral or bacterial exposure (Fig. [3](#jor23263-fig-0003){ref-type="fig"}). Genes down regulated at 1‐ and 6 weeks showed enrichment for *muscle* phenotypes; by contrast, 1 day and 12 weeks genes did not show enrichment for any mouse phenotypes. Genes associated with *abnormal glycogen* and *triglyceride level*s were also found to be enriched at 1 week post injury. These data suggest that at early stages post injury, inflammation, and vasculature are in play with the attempt to repair and remodel both cartilage and bone. However at later stages post injury, the enrichment in *abnormal bone and cartilage morphology* categories are consistent with a damaged joint that has accrued significant morphological changes in bone and cartilage such as articular cartilage erosion and osteophyte formation, which are consistent with the histological and micro‐CT evaluations (Fig. [1](#jor23263-fig-0001){ref-type="fig"}E--J).

Comparison With Gene Expression Changes Induced by DMM Surgery {#jor23263-sec-0015}
--------------------------------------------------------------

DMM is a widely used and validated animal model for studying PTOA.[13](#jor23263-bib-0013){ref-type="ref"} Gene expression profiling have been recently conducted on DMM injured mouse knee joints, and significant transcriptional changes were reported at 2‐, 4‐, and 16 weeks time points for whole‐joint derived RNA[28](#jor23263-bib-0028){ref-type="ref"} and at 1‐, 2‐, and 6 weeks time points for micro‐dissected articular cartilage derived RNA.[17](#jor23263-bib-0017){ref-type="ref"} We compared TC gene expression data to DMM model[17](#jor23263-bib-0017){ref-type="ref"}, [28](#jor23263-bib-0028){ref-type="ref"} to determine the commonalities and differences between TC induced and DMM induced PTOA, at the molecular level. 485 (whole joint; 472 up‐ and 13 down‐regulated) and 189 (micro‐dissected cartilage; 168 up‐ and 21 down‐regulated) of the DMM differentially expressed transcripts overlapped with our TC data, at least at one time point examined. A full list of these overlapping genes is provided in Supplementary Table S1. For significantly up‐regulated genes in whole joint RNA, 1 week post‐TC and 4 weeks post‐DMM injury had the largest overlap, with 382 shared (74.32% of TC genes) differentially expressed genes, while only 228 transcripts overlapped between the 1 week post‐TC and 2 weeks post‐DMM (whole joint). When micro‐dissected DMM cartilage was compared to our data, 1 week post‐TC and 2 weeks post DMM (cartilage) had the largest overlap, with 139 shared genes (27% of TC genes) (Table [4](#jor23263-tbl-0004){ref-type="table-wrap"}). Only 67 transcripts overlapped between the 1‐week post‐TC and 1‐week post‐DMM (cartilage). The 6 weeks TC data shared only 32 genes with the 6 weeks cartilage data but had a 125 gene overlap with the 4 weeks DMM whole joint data. Very few genes were found to overlap among the differentially down‐regulated transcripts or between our 12 weeks and the whole joint DMM 16 week data (Table [4](#jor23263-tbl-0004){ref-type="table-wrap"}).

###### 

Gene Expression Similarities Between TC (Tibial Compression) and DMM (Destabilization of Medial Meniscus) at Various Time Points Post Injury

  Time Point                     TC                                               
  ------------------------------ ----- ------- ------- ------- ----- ------- ---- -------
  DMM up‐regulated transcripts                                                    
  1 week (C)                     n/c   67      13.04   n/c     n/c                
  2 weeks (C)                    n/c   139     27.04   n/c     n/c                
  2 weeks (WJ)                   168   33.87   228     44.36   68    18.38   26   14.94
  4 weeks (WJ)                   262   52.82   382     74.32   125   33.78   36   20.69
  6 weeks (C)                    n/c   n/c     32      8.65    n/c                
  16 weeks (WJ)                  21    4.23    41      7.98    28    7.57    14   8.05

                                   1 Day (103)   1 Week (130)   6 Weeks (141)   12 Weeks (27)                    
  -------------------------------- ------------- -------------- --------------- --------------- ----- ------ --- ------
  DMM down‐regulated transcripts                                                                                 
  1 week (C)                       n/c           4              3.08            n/c             n/c              
  2 weeks (C)                      n/c           17             13.08           n/c             n/c              
  2 weeks (WJ)                     5             4.85           6               4.62            1     0.71   0   0.00
  4 weeks (WJ)                     9             8.74           6               4.62            1     0.71   0   0.00
  6 weeks (C)                      n/c           n/c            4               2.84            n/c              
  16 weeks (WJ)                    0             0.00           0               0.00            0     0.00   0   0.00

C, cartilage (Bateman *et al*.)^17^; WJ, whole joint (Loeser *et al*.)^18^; n/c comparison was not conducted.

Number of overlapping genes are presented as the net number of genes up‐ (a) or down‐ (b) regulated in both the TC and DMM datasets, as well as percentage of the entire gene expression data set described for the TC time points.

© 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

TC model uniquely identified 582 up‐, 295 down‐, and 15‐mixed (up or down at different time points) regulated genes (Suppl. Table S1). This includes several immune/inflammatory response related genes such as *Ccr2*, *C1qa*, *C1qb*, *C1qc*, and *Cfb*; bone development related genes such as *Spp1*, *Ctgf*, *Dmp1*, *Gabbr1*, and *Pth1r*; cell adhesion genes such as *Emilin1*, *Gpnmb*, *Itga5*, and *Stab1* and energy metabolism genes such as *Ndufa1*, *Ndufa2*, *Ndufb3*, *Uqcr10*, and *Sdhb*.

DISCUSSION {#jor23263-sec-0016}
==========

The TC induced ACL rupture model of PTOA is a new animal model that has not yet been widely explored to study mechanisms of joint OA development. This study provides the first account of whole genome expression profiles to obtain new insights into the temporal progression of the disease in the TC PTOA model. Despite being a noninvasive procedure, and exhibiting no obvious morphological or structural damages to tissues other than the ACL (Fig. [1](#jor23263-fig-0001){ref-type="fig"}C), we observed the largest transcriptional changes at early time points, with 599 and 644 transcripts being differentially expressed, at 1 day and 1 week post injury, respectively. Also, most of the differentially expressed genes were up‐regulated, with less than 30% of differentially expressed genes being significantly down‐regulated, at any time point examined.

Consistent with reports by Gardiner et al.[9](#jor23263-bib-0009){ref-type="ref"} where they examined transcriptional changes in micro‐dissected cartilage derived from DMM injured joints, we also identified *Tnn* (*tenasin N*) and *Fn1* (*fibronectin 1*) as two transcripts consistently up‐regulated at all time points examined (Table [1](#jor23263-tbl-0001){ref-type="table-wrap"}). Also, similar to previous reports on DMM gene expression time‐course experiments,[9](#jor23263-bib-0009){ref-type="ref"}, [28](#jor23263-bib-0028){ref-type="ref"} the TC model of PTOA also undergoes a decline in transcriptional changes with time, where by 12 weeks post injury, only 201 transcripts are differentially expressed, suggesting that the joint adapts to the injury, with time, to reach a new molecular homeostasis, despite the enormous articular cartilage loss evident at this time point (Fig. [1](#jor23263-fig-0001){ref-type="fig"}F).

In addition, our model captures many of the transcriptional changes previously reported for DMM damaged cartilage, both reported for whole joints and micro‐dissected cartilage. We identified several genes including *Mmp3*, *Errfi1*, *and C1qtnf3* with known arthritis phenotype as differentially regulated in TC data and both DMM datasets. *C1qtnf3* has previously been implicated in autoimmune arthritis[39](#jor23263-bib-0039){ref-type="ref"}; however, further studies are required to understand its role in OA. We also identified several regulators of Wnt signaling including *Sfrp1*, *Sfrp2*, *Sfrp4*, *Dkk2*, and *Dkk3* and TGFβ signaling including *Ltbp1*, *Fbn1*, and *Fbn2* commonly changed in both the TC and DMM models. Our 1 week data has the largest overlap with the 4 weeks post injury DMM[28](#jor23263-bib-0028){ref-type="ref"} whole joint data, where 74% of our up‐regulated transcripts were also found transcriptionally elevated in the DMM injured joints. We also found significant overlap between our 1 week post injury data and DMM injury pure cartilage data, where 67 up‐regulated genes (13%) overlapped with the 1 week and 139 up‐regulated genes (27%) overlapped with 2 weeks post DMM injury (Table [4](#jor23263-tbl-0004){ref-type="table-wrap"}). These data provides confirmation that the TC model recapitulates a large proportion of the gene expression reported for the DMM model, both at the whole joint and at the pure cartilage level. However these data also shows that these molecular changes happened at a faster rate in the TC model, suggesting that the TC injury may be a rapidly progressing PTOA model than DMM.

We also compared our data to previously published expression data of different human OA tissues including synovium,[6](#jor23263-bib-0006){ref-type="ref"} osteophyte,[10](#jor23263-bib-0010){ref-type="ref"} tibial plateau,[11](#jor23263-bib-0011){ref-type="ref"} articular cartilage,[8](#jor23263-bib-0008){ref-type="ref"}, [40](#jor23263-bib-0040){ref-type="ref"} and meniscus[7](#jor23263-bib-0007){ref-type="ref"} and found that majority of genes commonly differentially regulated between both human OA and TC induced mouse OA correspond to osteophyte and subchondral bone changes (Suppl. Table S2), consistent with osteophyte formation being a major hallmark of PTOA in humans and recapitulated in the TC mouse model examined here (Fig. [1](#jor23263-fig-0001){ref-type="fig"}G and H).

Interestingly, few genes up‐regulated in the TC PTOA time course are found to be significantly up‐regulated in the patient‐derived OA cartilage. In particular one gene, *Col6A2* is up‐regulated in TC joints, at all times points examined, but significantly up‐regulated in human OA articular cartilage only. Mutations in this protein are primarily associated with myopathies,[41](#jor23263-bib-0041){ref-type="ref"} but may also have an important role in ECM remodeling in PTOA. Serpines are peptidase inhibitors and Serpine2 has been shown to up‐regulated in cultured chondrocytes in response to IL‐1α to inhibit MMP13 expression. We find Serpine1 to be significantly up‐regulated at 1 day and 1 week post injury, and similarly this molecule is up‐regulated in OA articular cartilage, suggesting that the upregulation of this peptidase may represent a regulatory mechanism for repressing the expression of cartilage catabolic enzymes.

Several genes identified in our study including *Fndc1*, *Fads3*, *Edil3*, *C1qtnf6*, *Il1r1*, *Ptgs2*, *Rel*, *Tlr4*, and *Aldh1a2* were previously identified by genome wide association studies (GWAS) as potential OA, rheumatoid arthritis (RA), or ankylosing spondylitis (AS) susceptibility loci. These genes commonly altered in both PTOA and other degenerative joint diseases may highlight molecular components of potentially shared mechanisms that contribute to joint degeneration.

Our study also allowed us to examine transcriptional changes in several *lncRNAs*. We identified 18 *lncRNAs* differentially transcribed at least at one time point, 10 that were up‐ and 8 that were down‐regulated (Table [2](#jor23263-tbl-0002){ref-type="table-wrap"}). Two of these *lncRNAs*, *Dnm3os*, and *H19* have been previously described in the context of skeletal development[42](#jor23263-bib-0042){ref-type="ref"} or OA,[43](#jor23263-bib-0043){ref-type="ref"} but all other *lncRNAs* identified herein have yet to be studied in the context of PTOA development. Furthermore, since we do not observe broad activation or repression across all time points examined, but rather see groups of *lncRNAs* transcriptionally changed at single time points, we speculated these noncoding RNAs may have unique functions to modulate the transcription of "function specific" cohorts of genes. Also, it would be interesting to determine whether some of these *lncRNAs* are modulated by the immune system, since initial changes in inflammation may be able to trigger large cascades of gene expression by repressing or activating these regulatory RNAs.

A list of possible genes that remain to be explored as candidate biomarkers or local joint therapeutics includes *Ssc5d*, a gene primarily expressed in monocytes/macrophages and T‐lymphocytes[44](#jor23263-bib-0044){ref-type="ref"} and *Cemip* (*KIAA1199*), a gene involved in hyaluronan (HA) metabolism.[45](#jor23263-bib-0045){ref-type="ref"} SSC5D, a soluble scavenger protein, was previously identified to be elevated in synovial fluid of OA patients.[46](#jor23263-bib-0046){ref-type="ref"} HA plays an important role in maintaining the integrity of articular cartilage by providing lubrication between the femoral and tibial surfaces. *Cemip* (KIAA1199) is a gene that enhances HA catabolism in the synovium[45](#jor23263-bib-0045){ref-type="ref"} and improves growth and angiogenesis of synovial tissue.[47](#jor23263-bib-0047){ref-type="ref"} However its role in OA developing joints has not yet been explored and inhibitors of *Cemip* may potentially prevent cartilage degradation post injury.

Our study also identified several novel genes including *Suco, Sorcs2*, and *Medag*. *Suco* (*Opt*) encodes a widely expressed rough endoplasmic reticulum‐localized integral membrane protein. Mice lacking *Suco* develop acute onset of skeletal defects including impaired bone formation and spontaneous fractures.[48](#jor23263-bib-0048){ref-type="ref"} *Suco* is \> 2‐fold up‐regulated at 6 weeks post injury suggesting a role in aberrant bone remodeling and/or osteophyte formation. *Sorcs2* is a member of vacuolar protein sorting 10 family proteins (*VPS10Ps*) with a potential role in protein trafficking and cell signaling.[48](#jor23263-bib-0048){ref-type="ref"} Recent GWAS study identified *Sorcs2* as a candidate loci associated with cranial cruciate ligament rupture in Newfoundland dogs,[49](#jor23263-bib-0049){ref-type="ref"} however this gene has not been previously studied in the context of osteoarthritis. *Medag*, a gene we found up‐regulated at 1 day, 1‐ and 6 weeks has been shown to play a role in adipose tissue development[50](#jor23263-bib-0050){ref-type="ref"}; however, its role in osteoarthritis has yet to be explored.

There are a few potential limitations to our study. First, we utilized the contralateral joint as controls instead of age matched sham injured joints. Because of this, it is difficult to distinguish between changes mediate by the injury that had systemic effects on both joints. In addition, there may also be changes occurring in the contralateral as a result of altered loading (more use of one joint) and changes in the injured joint/leg due to reduced mobility, disuse and pain. Second, because we are sequencing whole joints instead of individual tissues of the joint, to tease out where the gene expressions are coming from presents a challenge. However, because OA is considered a "joint disease," comprehensive intact joint analysis may allow us to identified changes in tissues that may not normally be assumed to contribute to cartilage degradation or remodeling, such as muscle. Because of these caveats, we may lose some genes that are differentially expressed in a small area, or genes that are normally expressed broadly, but are affected regionally. These challenges may be overcome by examining candidate proteins for their tissue specific expression.

Our study uniquely introduces the gene expression changes associated with a new, noninvasive model of PTOA.[34](#jor23263-bib-0034){ref-type="ref"} This model closely mimics human ACL injuries resulted from a single high impact damage that leads to PTOA development. Our data provides evidence that a significant number of changes in the TC model correlate with both whole joint derived RNA and micro‐dissected cartilage derived RNA from the DMM model. Our study also highlights the differences between two models at the molecular level where our earlier time points (1 week) revealed more similarities with the later DMM time points (4 weeks), suggesting that TC model may be a more rapidly progressing PTOA model. Therefore, the TC model may be more suitable for investigating rapidly progressing joint failure and events occurring at earlier stages of traumatic injury. The pathways and candidate genes presented herein represent additional opportunities for investigating new potential therapeutic targets and susceptibility loci for PTOA.
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